Global private equity investment in the European healthcare industry fell by more than a quarter in 2022, with the second half of the year seeing a particularly sluggish performance, according to S&P Global Market Intelligence analysis.

The aggregate transaction value for private equity investments in the space came to $18.88 billion across 813 deals in 2022, compared to $25.79 billion from 983 deals a year earlier, according to S&P Global Market Intelligence data.

Q4 2022 hedge fund letters, conferences and more

Key Highlights

Deal volume for all of 2022 ended up peaking in the first quarter, with 234 transactions bringing in $7.50 billion. In the final three months of the year, investments were down by more than half at $3.28 billion. Healthcare services received the greatest investment, with private equity pouring in $7.01 billion, followed by pharmaceuticals at $3.97 billion and biotechnology at $2.93 billion. The three subsectors accounted for more than 70% of the total private equity investments in European healthcare.

Largest Deals

KKR & Co. Inc.'s acquisition of Spanish fertility company IVIRMA Global SL for $3.30 billion was the largest private equity investment in the European healthcare industry in 2022. The pending acquisition of Sweden-based Envirotainer AB by EQT Partners AB and Mubadala Investment Co. PJSC for $2.99 billion marked the second-largest deal of the year. The investor group agreed to acquire the healthcare services company from Cinven Ltd. and Novo Holdings A/S in June 2022.

Next was Unither Pharmaceuticals SAS' proposed buyout by an investor group that included IK Partners and GIC Pte. Ltd. for $1.60 billion from Keensight Capital, Parquest Capital and Ardian. Unither's management team, along with Keensight and Parquest, are reinvesting in the pharmaceuticals company.

Source valuewalk